PARIS, October 27, 2026 — AZmed, one of the leading AI companies in medical imaging,
today announced that its FDA-cleared AZtrauma and AZchest X-ray AI applications are
available through RapidAI, a global leader in enterprise clinical AI, via the Rapid Enterprise
Platform. The applications join a portfolio of 50+ clinical solutions that support radiologists
and care teams across the patient journey, bringing AZmed’s X-ray analysis capabilities into
a connected platform used by more than 2,500 hospitals.
X-ray findings can shape urgent decisions about treatment and follow-up, making timely
interpretation and communication essential. AI can help radiologists identify suspected
abnormalities and prioritize exams for review, while a shared clinical platform makes those
insights accessible to the care teams acting on them. This connects support for the
radiologist’s read with the coordination needed for next steps in care. In the U.S., AZtrauma
detects fractures, joint effusions and dislocations on musculoskeletal X-rays across adult
and pediatric (ages ≥ 2) populations. AZchest covers five findings on frontal chest X-rays:
lung nodules, consolidation, pneumothorax, pleural effusion and increased cardiothoracic
ratio, with triage and notification for pneumothorax and pleural effusion.
The integration gives teams a consistent way to access and act on AI findings across clinical
specialties, reducing the need to navigate separate AI tools. Radiologists receive AZmed
results and worklist prioritization through Rapid Navigator Pro, while emergency physicians
and orthopedic teams access results through the Rapid Mobile App, giving them shared
clinical context to coordinate next steps.
For health systems, a single IT deployment simplifies adding and managing AZmed’s
applications alongside RapidAI solutions. Rapid Edge Cloud provides resilient infrastructure,
while Rapid Insights gives health systems centralized visibility into AI program utilization and
performance to support oversight as they expand their use of clinical AI.
“AZtrauma and AZchest are built to fit the way a radiology department already works, not to
add another screen to it,” said Julien VIDAL, CEO of AZmed. “Through the Rapid Enterprise
Platform, radiologists read with our results in the same place as the rest of their AI, and the
emergency and orthopedic teams act on those same findings.”
The collaboration advances AZmed’s expansion in the U.S., making its FDA-cleared X-ray
AI available to health systems through RapidAI’s established clinical network.
About AZmed
Founded in 2018, AZmed is a European MedTech company developing AI solutions for
medical imaging. Its Rayvolve AI suite includes FDA-cleared and CE-marked tools, while its Rayscan line is CE-marked. Used by more than 2,500 healthcare facilities worldwide,
AZmed’s solutions improve diagnostic consistency and operational efficiency in medical
imaging. Additional resources on AI-supported fracture detection and chest imaging are
available on AZmed’s website.
About RapidAI
RapidAI is a global leader in enterprise clinical AI, trusted by more than 2,500 hospitals across 100+ countries and backed by 800+ clinical studies. The Rapid Enterprise™ Platform combines 50+ RapidAI-developed and third-party algorithms spanning neurology, cardiac and vascular, trauma, and oncology care. Paired with enterprise workflow solutions that connect radiology and clinical teams throughout the patient journey, it turns imaging and patient data into actionable clinical context, moving radiologists and clinicians from detection to confident action. Powered by Rapid Edge Cloud and built to integrate with existing workflows and health IT systems, it helps health systems reduce fragmentation, improve collaboration, and deliver faster, more consistent care across the enterprise.
For more information, visit rapidai.com.
